Stopping or continuing platelet inhibitors after cryptogenic stroke at young age: STOP trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513092-40-00

Acronym

114180

Enrollment

1316

Registered

2024-08-04

Start date

2024-12-05

Completion date

Unknown

Last updated

2025-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Brief summary

A composite endpoint of major vascular events, defined as TIA with imaging confirmation, stroke, myocardial infarction, or death from vascular causes.

Detailed description

Major bleeding, All-cause mortality, Cost-effectiveness, Quality of life

Interventions

DRUGACETYLSALICYLIC ACID

DRUGPlavix 75 mg film-coated tablets

DRUGClopidogrel Viatris 75 mg film-coated tablets

DRUGDIPYRIDAMOLE

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
A composite endpoint of major vascular events, defined as TIA with imaging confirmation, stroke, myocardial infarction, or death from vascular causes.	—

Secondary

Measure	Time frame
Major bleeding, All-cause mortality, Cost-effectiveness, Quality of life	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026